Ginai A Z
Br J Radiol. 1987 Apr;60(712):343-6. doi: 10.1259/0007-1285-60-712-343.
The clinical use of Hexabrix (May and Baker) was started about 3.5 years ago for the radiological evaluation of patients in whom the possibility of leakage of contrast medium outside the upper gastrointestinal tract, particularly the oesophagus, was anticipated. The majority (greater than 70%) of the patients were in their early post-operative period. No adverse reactions because of the use of Hexabrix were encountered.
约3.5年前开始临床使用海克沙醇(May and Baker公司生产),用于对预计有造影剂漏出上消化道尤其是食管可能性的患者进行放射学评估。大多数(超过70%)患者处于术后早期。未发现因使用海克沙醇而出现的不良反应。